Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
09 2023
Historique:
revised: 07 06 2023
received: 07 12 2022
accepted: 12 06 2023
medline: 20 9 2023
pubmed: 4 7 2023
entrez: 4 7 2023
Statut: ppublish

Résumé

Respiratory tract infections (RTIs) are a burden to global health, but their characterization is complicated by the influence of seasonality on incidence and severity. The Re-BCG-CoV-19 trial (NCT04379336) assessed BCG (re)vaccination for protection from coronavirus disease 2019 (COVID-19) and recorded 958 RTIs in 574 individuals followed over 1 year. We characterized the probability of RTI occurrence and severity using a Markov model with health scores (HSs) for four states of symptom severity. Covariate analysis on the transition probability between HSs explored the influence of demographics, medical history, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), or influenza vaccinations, which became available during the trial, SARS-CoV-2 serology, and epidemiology-informed seasonal influence of infection pressure represented as regional COVID-19 pandemic waves, as well as BCG (re)vaccination. The infection pressure reflecting the pandemic waves increased the risk of RTI symptom development, whereas the presence of SARS-CoV-2 antibodies protected against RTI symptom development and increased the probability of symptom relief. Higher probability of symptom relief was also found in participants with African ethnicity and with male biological gender. SARS-CoV-2 or influenza vaccination reduced the probability of transitioning from mild to healthy symptoms. Model diagnostics over calendar-time indicated that COVID-19 cases were under-reported during the first wave by an estimated 2.76-fold. This trial was performed during the initial phase of the COVID-19 pandemic in South Africa and the results reflect that situation. Using this unique clinical dataset of prospectively studied RTIs over the course of 1 year, our Markov Chain model was able to capture risk factors for RTI development and severity, including epidemiology-informed infection pressure.

Identifiants

pubmed: 37401774
doi: 10.1002/psp4.13006
pmc: PMC10508522
doi:

Substances chimiques

BCG Vaccine 0

Banques de données

ClinicalTrials.gov
['NCT04379336']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1250-1261

Informations de copyright

© 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Acta Biotheor. 2021 Dec 27;70(1):8
pubmed: 34958426
CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):87-109
pubmed: 27884052
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296675
Respir Med. 2007 Sep;101(9):1845-63
pubmed: 17544265
Ann Am Thorac Soc. 2014 Mar;11(3):404-6
pubmed: 24673696
CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1250-1261
pubmed: 37401774
BMC Med. 2019 Aug 22;17(1):164
pubmed: 31438953
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1305-1309
pubmed: 32941415
Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594
pubmed: 28176362
J Infect Dis. 2018 Apr 11;217(9):1356-1364
pubmed: 29390105
EClinicalMedicine. 2022 Jun;48:101414
pubmed: 35582122
Pharm Res. 1998 Sep;15(9):1463-8
pubmed: 9755901
Sci Rep. 2023 Sep 28;13(1):16292
pubmed: 37770596
Expert Rev Respir Med. 2019 Jan;13(1):63-77
pubmed: 30518278
Lancet HIV. 2021 Sep;8(9):e554-e567
pubmed: 34363789
Clin Pharmacol Ther. 2009 Oct;86(4):387-95
pubmed: 19626001
Int J Environ Res Public Health. 2021 Oct 21;18(21):
pubmed: 34769577
Int J Infect Dis. 2015 Nov;40:15-6
pubmed: 26417877
Annu Rev Virol. 2020 Sep 29;7(1):83-101
pubmed: 32196426

Auteurs

Rob C van Wijk (RC)

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Laurynas Mockeliunas (L)

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Caryn M Upton (CM)

TASK, Cape Town, South Africa.

Jonathan Peter (J)

Department of Medicine, University of Cape Town Lung Institute and Division of Allergy and Clinical Immunology, University of Cape Town, Cape Town, South Africa.

Andreas H Diacon (AH)

TASK, Cape Town, South Africa.

Ulrika S H Simonsson (USH)

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH